Onkure Therapeutics, Inc. (OKUR) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on November 7, 2024, by Onkure Therapeutics, Inc. (formerly Reneo Pharmaceuticals, Inc.). The filing addresses significant corporate governance changes and provides supplemental financial information related to the merger consummated on October 4, 2024, between Reneo Pharmaceuticals, Inc. and Legacy OnKure, Inc.
Key Financial Metrics
This Form 8-K does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Instead, it serves as a vehicle to incorporate by reference the following unaudited financial documents filed as exhibits:
- Unaudited interim financial statements of Legacy OnKure as of September 30, 2024 (Exhibit 99.1).
- Management's Discussion and Analysis (MD&A) for Legacy OnKure for the nine months ended September 30, 2024 (Exhibit 99.2).
- Unaudited pro forma condensed combined financial information for Reneo and Legacy OnKure (Exhibit 99.3).
Investors must refer to the attached exhibits for specific financial data points.
Material Changes
The filing reports two primary material events:
- Change in Certifying Accountant: On November 7, 2024, the Audit Committee dismissed Ernst & Young LLP (EY) as the independent registered public accounting firm. EY's reports for fiscal years 2022 and 2023 did not contain adverse opinions, though the 2022 report included an explanatory paragraph regarding the Company's ability to continue as a going concern. No disagreements or reportable events occurred during the tenure of EY.
- Appointment of New Accountant: On November 7, 2024, the Audit Committee engaged KPMG LLP as the new independent registered public accounting firm. KPMG previously served as the auditor for Legacy OnKure prior to the merger.
- Merger Completion: The merger between Reneo and Legacy OnKure was consummated on October 4, 2024. This filing supplements the Form 10-Q filed on November 7, 2024, which only contained Reneo's financials, by adding Legacy OnKure's financials and pro forma combined data.
Guidance, Outlook, and Risks
The filing text does not provide specific forward-looking guidance, management commentary on future operations, or a detailed list of risks beyond the historical context of the going concern qualification noted in EY's 2022 report. The primary focus is on the transition of audit firms and the disclosure of financial statements resulting from the recent merger.
Investor Verification Checklist
- Review Exhibit 99.1 for Legacy OnKure's unaudited interim financial statements as of September 30, 2024.
- Examine Exhibit 99.3 for pro forma combined financial information to understand the post-merger financial position.
- Verify the letter from Ernst & Young LLP (Exhibit 16.1) to confirm their agreement with the Company's statements regarding the dismissal.
- Confirm the details of the merger agreement and the specific terms of the combination between Reneo and Legacy OnKure.